pharmaphorum
OCTOBER 19, 2020
Regular fliers are used to long queues to clear security – but a rigorous COVID-19 testing regime could be added to pre-flight checks backed by a digital “health passport” to prove passengers are free from the coronavirus. The UK is the latest country to test the scheme that allows passengers to demonstrate their coronavirus status as part of a global framework for COVID-safe air travel.
Outsourcing Pharma
OCTOBER 19, 2020
The agencyâs Solidarity Therapeutics Trial examined a range of drugs repurposed for COVID-19 treatment, finding nearly no effect on patient mortality.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
OCTOBER 21, 2020
Pharmaceutical and life sciences industries are growing in importance across country
Drug Patent Watch
OCTOBER 20, 2020
Annual Drug Patent Expirations for XIFAXAN Xifaxan is a drug marketed by Salix Pharms and is included in two NDAs. It is available from two suppliers. There are twenty-six patents…. The post New patent for Salix Pharms drug XIFAXAN appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
OCTOBER 22, 2020
Cancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient advocate Megan-Claire Chase. No one gets through cancer unscathed. People are usually left with a mixture of treatment aftereffects, toxic positivity, and lingering anger to deal with. Megan-Claire Chase , a fierce patient advocate who has been blogging about her experiences since she was diagnosed with breast cancer in 2015, said the disease never went away.
Pharma Mirror
OCTOBER 22, 2020
By Rotem Shor, Medisafe Chief Technology Officer Technology and health have experienced a convergence in the last few years, leading to a new state of digital health that is transforming how we live and work. But there is a greater science behind it that analyzes tremendous amounts of data to shape and personalize our health. The post Using Behavioral Science in A Digital World appeared first on Pharma Mirror Magazine.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Patent Watch
OCTOBER 23, 2020
Annual Drug Patent Expirations for POMALYST Pomalyst is a drug marketed by Celgene and is included in one NDA. It is available from one supplier. There are eleven patents protecting…. The post New patent for Celgene drug POMALYST appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
OCTOBER 19, 2020
As part of our series of opinion pieces from leaders at Janssen, the company’s Maria Raad looks at how we can embrace tech and data science to overcome increasing pressures on healthcare systems. For the next generation born in the western world, living to be 100 will be the norm. While this seems like a desirable aspiration for our grandchildren, it adds new pressures on our healthcare systems.
Outsourcing Pharma
OCTOBER 19, 2020
The CRO and life-sciences tech firm collaborated on a solution capable of meeting challenges tied to starting and conducting global clinical trials.
Pharma Times
OCTOBER 19, 2020
Chief executive of trade body warns no-deal could affect medicines supply
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Patent Watch
OCTOBER 22, 2020
Annual Drug Patent Expirations for UPNEEQ Upneeq is a drug marketed by Rvl Pharms and is included in one NDA. There are two patents protecting this drug. This drug has…. The post New patent for Rvl Pharms drug UPNEEQ appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
OCTOBER 23, 2020
Novartis is opening a new digital health innovation hub in Canada to help develop “scalable, digital solutions” for patients and healthcare providers. The Canadian Biome Digital Innovation Hub will be based in Montreal at the artificial intelligence research institute, Mila. The institute formed a strategic alliance with Novartis in 2019. Canada is the latest country to join a global network of hubs opened by Novartis.
Outsourcing Pharma
OCTOBER 20, 2020
A leader from a New Zealand-based CRO talks about the countryâs handling of the pandemic, and how their low rates are making sponsors take notice.
Pharma Times
OCTOBER 20, 2020
System captures and harvests intact circulating tumour cells for analysis
Drug Patent Watch
OCTOBER 22, 2020
Annual Drug Patent Expirations for POMALYST Pomalyst is a drug marketed by Celgene and is included in one NDA. It is available from one supplier. There are eleven patents protecting…. The post New patent expiration for Celgene drug POMALYST appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
OCTOBER 19, 2020
Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its Tecartus therapy for mantle cell lymphoma. The EMA’s human drugs advisory committee recommended approval of Tecartus (brexucabtagene autoleucel; formerly KTE-X19 ) for relapsed or refractory MCL setting up a formal approval by the regulator in the coming weeks.
NY Times
OCTOBER 22, 2020
The move indicated that the drug had cleared more rigorous hurdles since it was given emergency authorization in May.
Pharma Times
OCTOBER 19, 2020
Dupixent, Forxiga and Opdivo were also recommended for therapeutic extensions
Drug Patent Watch
OCTOBER 23, 2020
Annual Drug Patent Expirations for IMVEXXY Imvexxy is a drug marketed by Therapeuticsmd Inc and is included in one NDA. It is available from one supplier. There are eight patents…. The post New patent for Therapeuticsmd Inc drug IMVEXXY appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
OCTOBER 21, 2020
Scientists say on-skin printing could be used to create on-body sensors to monitor physiological signals and devices to wirelessly transmit the data. A team led by Huanyu Cheng from Penn State University, say the sensors are capable of precisely and continuously capturing temperature, humidity, blood oxygen levels and heart performance signals. The next stage on the project is to target specific application, for example to develop a sensor network that could monitor symptoms associated with COVI
Outsourcing Pharma
OCTOBER 20, 2020
A leader from the company advises planning ahead when filing investigational new drug applications to avoid wasting time, work and money later.
Pharma Times
OCTOBER 22, 2020
Investigational vaccine candidate was generally safe across all dose and age groups
NY Times
OCTOBER 20, 2020
All the weak points of American health care — testing delays, communication breakdowns, inequity — are working against this potential treatment.
pharmaphorum
OCTOBER 20, 2020
Huge demand for ventilators and patient monitors spurred third quarter sales for Royal Philips, the company announced. The Dutch health technology group reported sales of €4.98bn, a 10% year-over-year growth. The connected care business, which includes patient monitors and ventilators saw the biggest rise, increasing by 42%. Philips said it had ramped up production of the equipment to meet global demand.
Drug Patent Watch
OCTOBER 22, 2020
Annual Drug Patent Expirations for THALOMID Thalomid is a drug marketed by Celgene and is included in one NDA. It is available from one supplier. There are nine patents protecting…. The post New patent expiration for Celgene drug THALOMID appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
OCTOBER 20, 2020
CHMP grants Palforzia a positive opinion for the treatment of peanut allergic patients
Outsourcing Pharma
OCTOBER 22, 2020
The rare-disease organization will work with Rady Childrenâs Institute for Genomic Medicine to help patients and their families connect with solutions.
pharmaphorum
OCTOBER 22, 2020
Sarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with $107 million in backing from his former employer and three high-profile life sciences investors. Rare disease specialist Sarepta is putting up $15 million of that first-round financing, with the remainder coming from Perceptive Advisors, Bain Capital Life Sciences, and RA Capital Management.
Drug Patent Watch
OCTOBER 20, 2020
Annual Drug Patent Expirations for OMNARIS Omnaris is a drug marketed by Covis Pharma Bv and is included in one NDA. It is available from one supplier. There are three…. The post New patent expiration for Covis Pharma drug OMNARIS appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
OCTOBER 23, 2020
Collaboration will involve applying machine learning for research into rare blood diseases
Outsourcing Pharma
OCTOBER 22, 2020
The latest iteration of BBK Worldwide's Study Voices survey reveals thoughts on decentralized studies, telehealth and other trial technology.
pharmaphorum
OCTOBER 20, 2020
The UK government has signed a contract to develop a controversial COVID-19 human challenge trial, where participants will be deliberately infected in a controlled environment with coronavirus to test whether a vaccine is effective. Contract research organisation (CRO) hVIVO, a subsidiary of Open Orphan, has signed the contract with the UK government to develop the trial model.
Drug Patent Watch
OCTOBER 23, 2020
Annual Drug Patent Expirations for KALYDECO Kalydeco is a drug marketed by Vertex Pharms Inc and Vertex Pharms and is included in two NDAs. It is available from one supplier.…. The post New patent for Vertex Pharms drug KALYDECO appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Times
OCTOBER 21, 2020
New film and study highlight the effects of 'long COVID'
Outsourcing Pharma
OCTOBER 20, 2020
The generic drug manufacturer is working with Kit Check to incorporate the company's drug supply-chain management technology into two of its products.
Expert insights. Personalized for you.
140 
Let's personalize your content